Impact News +++ (3⁺) Chart Tracker: AIXTRON, AMD (Stock3) +++ AIXTRON Aktie +3,82%

JACOBIO Aktie

>JACOBIO Aktienkurs

0.91 EUR -8.5% (Tradegate)

Ask: 0.915 EUR / 3306 Stück

Bid: 0.8 EUR / 3696 Stück

Tagesumsatz: 1238 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

JACOBIO Aktie über LYNX handeln

Intraday

1 Jahr

>JACOBIO Performance

1 Woche: -0,3%

1 Monat: +36,0%

3 Monate: -13,3%

6 Monate: +96,5%

1 Jahr: +501,5%

laufendes Jahr: +520,3%

>JACOBIO Aktie

Name:

JACOBIO PHARMACEUTICALS

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

KYG4987A1094 / A2QK1R

Symbol/ Ticker:

77V (Frankfurt)

Kürzel:

FRA:77V, ETR:77V, 77V:GR

Index:

Webseite:

https://www.jacobiopharma..

Profil:

Jacobio Pharmaceuticals Group Co., Ltd. is a bioph..
>Volltext..

Marktkapitalisierung:

768.71 Mio. EUR

Unternehmenswert:

676.79 Mio. EUR

Umsatz:

23.7 Mio. EUR

EBITDA:

-7.18 Mio. EUR

Nettogewinn:

-5.32 Mio. EUR

Gewinn je Aktie:

-0.01 EUR

Schulden:

35.57 Mio. EUR

Liquide Mittel:

118.39 Mio. EUR

Operativer Cashflow:

-2.09 Mio. EUR

Bargeldquote:

7.15

Umsatzwachstum:

687.05%

Gewinnwachstum:

88.71%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

JACOBIO

Letzte Datenerhebung:

22.12.25

>JACOBIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 788.74 Mio. St.

Frei handelbar: 52.93%

Leerverk. Aktien: -

Rückkaufquote: 0.02%

Mitarbeiter: 257

Umsatz/Mitarb.: 0.07 Mio. EUR

Analysten:

Analystenrating: Neutral

Kursziel: 5.7%

Bewertung:

KGV: -

KGV lG: -

KUV: 28.74

KBV: 7.64

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 88.02%

Gewinnmarge: -22.43%

Operative Marge: -42.28%

Managementeffizenz:

Gesamtkaprendite: -3.46%

Eigenkaprendite: -5.08%

>JACOBIO Peer Group

Es sind 101 Aktien bekannt.

>JACOBIO Chart & Kurs - Tradegate

>JACOBIO News

22.12.25 - 04:42	Jacobio Strikes New Cancer Drug Deal with AstraZeneca (Bloomberg)
	Hong Kong-listed Chinese biotech firm Jacobio Pharma says it hopes to commercialize a new drug that it's developing with AstraZeneca. Speaking on Bloomberg's "The China Show," the company's Co-CEO, Chief Medical Officer and Global Head of R&D Andrea Wang-Gillam discusses the significance of the Pan-KRAS inhibitor and her company's business outlook. (Source: Bloomberg)...

21.12.25 - 16:12	Jacobio Pharma Signs Agreement With AstraZeneca On Pan-KRAS Inhibitor JAB-23E73 (AFX)
	LONDON (dpa-AFX) - Jacobio Pharma (1167.HK) announced that it has entered into a strategic agreement with AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) for its proprietary Pan-KRAS inhibitor, JAB-23E73......

21.12.25 - 13:18	Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73 (PR Newswire)
	BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive exclusive development and commercialisation rights outside of......

24.10.25 - 02:01	Jacobio Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International Conference (PR Newswire)
	BEIJING and SHANGHAI and BOSTON, Oct. 23, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it presented the pre-clinical data of its internally discovered pan-KRAS inhibitor JAB-23E73 in a poster presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular......

15.10.25 - 17:06	Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline (PR Newswire)
	BEIJING and SHANGHAI and BOSTON, Oct. 15, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and an......

26.09.25 - 02:51	Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth (PR Newswire)
	BEIJING, SHANGHAI and BOSTON, Sept. 25, 2025 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million......

29.08.25 - 22:18	Jacobio Pharmaceuticals Group reports 1H results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.08.25 - 18:30	Jacobio Pharma Announces 2025 Interim Results (PR Newswire)
	BEIJING and SHANGHAI and BOSTON, Aug. 29, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced its interim results for the six months ended June 30, 2025. During the reporting period, the Company achieved revenue of RMB45.7 million, representing a 100% increase compared with the......

03.07.25 - 02:33	Jacobio′s IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted (PR Newswire)
	BEIJING, SHANGHAI and BOSTON, July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center for Drug Evaluation (CDE) in......

19.03.25 - 14:45	Jacobio Pharma Announces 2024 Annual Results (PR Newswire)
	BEIJING, SHANGHAI and BOSTON, March 19, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RMB320 million cash inflows. By the end of 2024, cash......

07.01.25 - 01:33	The Registrational Clinical Data of Glecirasib was Published in Nature Medicine (PR Newswire)
	BEIJING, SHANGHAI and BOSTON, Jan. 6, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced today that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been......

09.12.24 - 02:54	Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH (PR Newswire)
	BEIJING, SHANGHAI and BOSTON, Dec. 8, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Kaum einer, der heute die moderne Medizin kritisiert, wäre ohne sie noch am Leben. - Dr. Gerhard Kocher

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram